Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 5Neoplasm Metastasis 4Urinary Bladder Neoplasms 3Recurrence 2Melanoma 2Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma in Situ 1Breast Neoplasms 1

Interventions

enfortumab vedotin 4pembrolizumab 3vinflunine 2Ramucirumab 2Gemcitabine 2Docetaxel 2Cisplatin 2rucaparib 1Standard of Care 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide 1Molecular Diagnostic Techniques 1LHRH, lysine(6)-doxorubicin 1Immunotherapy 1Icrucumab 1IMC-18F1 1Drug Therapy 1Carboplatin 1Biological Therapy 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Ureteral Neoplasms × ALT-801 × Clear all
NCT01326871 2024-06-25

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Altor BioScience

Phase 1/2 Completed
68 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis, Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡